Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: A single centre, prospective cohort study

Journal of Clinical Virology

Volumn 68, Issue , 2015, Pages 37-42

  Durante Mangoni, Emanuele ^a   Andini, Roberto ^a   Pinto, Daniela ^a   Iossa, Domenico ^a   Molaro, Rosa ^a   Agrusta, Federica ^a   Casillo, Roberta ^a   Grimaldi, Maria ^a   Utili, Riccardo ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cytomegalovirus; Immunosuppression; Opportunistic infection; Prognosis; Transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL PNEUMONIA; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DUODENUM ULCER; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; NOCARDIA; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; SURVIVOR; VIREMIA; VIRUS REPLICATION; AGED; CYTOMEGALOVIRUS INFECTIONS; INCIDENCE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PATHOLOGY;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANT RECIPIENTS;

EID: 84930516550     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.04.017     Document Type: Article

References (15)

1. Razonable R.R., et al. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin. Microbiol. Rev. 2013, 26:703-727.
2. McDevitt L.M., et al. Etiology and impact of cytomegalovirus disease on solid organ transplant recipients. Am. J. Health Syst. Pharm. 2006, 63:S3.
3. Lumbreras C., et al. Cytomegalovirus infection in solid organ transplant recipients. Clin. Microbiol. Infect. 2014, 20:19-26.
4. Razonable R.R., Humar A., The AST Infectious Diseases Community of Practice Cytomegalovirus in solid organ transplantation. Am. J. Transpl. 2013, 13:93-106.
5. Kotton C.N., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779-795.
6. Snydman D.S., et al. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant. Proc. 2011, 43:S1-S17.
7. Potena L., et al. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr. Opin. Infect. Dis. 2007, 20:425-431.
8. Potena L., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82:398-405.
9. Kamar N., et al. Alteration of direct and indirect effects of cytomegalovirus. Exp. Clin. Transplant. 2007, 5:727-730.
10. Potena L., et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J. Heart Lung Transplant. 2009, 28:461-467.
11. De Santo L.S., et al. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy. Transplant. Proc. 2005, 37:2684-2687.
12. Kobashigawa J., et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl. Infect. Dis. 2012, 0:1-13.
13. Viganò M., et al. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study. Transpl. Infect. Dis. 2010, 12:23-30.
14. Hill J.A., et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007, 84:1436-1442.
15. Casillo R., et al. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients. Transplant. Proc. 2004, 36:651-653.